Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F22%3AN0000014" target="_blank" >RIV/00023728:_____/22:N0000014 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/22:10442308 RIV/00216208:11110/22:10442308 RIV/00216208:11130/22:10442308

Result on the web

<a href="https://doi.org/10.1177/1759720X221081649" target="_blank" >https://doi.org/10.1177/1759720X221081649</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/1759720X221081649" target="_blank" >10.1177/1759720X221081649</a>

Result language

angličtina

Original language name

Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA

Original language description

The administration of biologic disease-modifying antirheumatic drugs, including tumor necrosis factor (TNF)-alpha inhibitors, is observed to interfere with the disease activity and progression. In this study, we aimed to assess the effectiveness and response predictors of adalimumab (ADA), a TNF-alpha blocker, in patients with axial spondyloarthritis (AxSpA). This study was a historical prospective, registry-based observational study on patients with AxSpA treated with first-line ADA after conventional drug failure. For evaluation and comparison, patients were divided into three groups according to the number of years from AxSpA diagnosis to initiation of ADA treatment: (A) <5years, (B) 5-10years, and (C) >10years. The assessment instruments ankylosing spondylitis disease activity score (ASDAS), Bath ankylosing spondylitis activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), health assessment questionnaire (HAQ), Short Form 36 questionnaire (SF-36), and EuroQoL 5 dimension questionnaire (EQ-5D] were regularly administered for up to 24 months of follow-up. This study included 1043 patients with AxSpA (9.2% with non-radiographic AxSpA, 68.9% men). By month 6, a significantly higher proportion of patients with ASDAS remission (<1.3) was achieved upon earlier intervention in group A (30.1%) and B (32.9%) than in the late intervention group C (22.6%) (p <= 0.05). At month 6, lower age and better BASFI at treatment initiation were identified as the strongest predictors of ASDAS remission in both univariable [odds ratio (OR): 0.956, p <= 0.001; OR: 0.834, p <= 0.001, respectively] and multivariable analyses (OR: 0.963, p <= 0.001; OR: 0.859, p <= 0.001, respectively). Earlier intervention also led to improvement in most patient-reported outcomes (PROs) based on HAQ, SF-36, and EQ-5D. Results from the ATTRA registry concur with previous clinical trials that supported efficacy of TNF-alpha blockers and showed better treatment outcomes with early interventions, including reduction of disease activity and improvement in PROs. We identified age and BASFI as the main factors influencing treatment effectiveness

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30226 - Rheumatology

Project

<a href="/en/project/NU20-05-00320" target="_blank" >NU20-05-00320: Neutrophils in juvenile idiopathic arthritis: biomarkers with potential to improve clinical treatment decisions and patient care</a><br>

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Therapeutic Advances Musculoskeletal Disease

ISSN

1759-720X

e-ISSN

1759-7218

Volume of the periodical

14

Issue of the periodical within the volume

Art. Nr. 1759720X221081649.

Country of publishing house

GB - UNITED KINGDOM

Number of pages

13

Pages from-to

1-13

UT code for WoS article

000772688100001

EID of the result in the Scopus database

2-s2.0-85126758508